HEALTH EQUITY IMPACTS OF ALTEPLASE FOR ISCHEMIC STROKE IN THE UNITED STATES: A DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS

被引：0
|
作者：
Majda, T. [1 ]
Kowal, S. [1 ]
Mearns, E. S. [1 ]
Purdon, B. [1 ]
机构：
[1] Genentech Inc, South San Francisco, CA USA
来源：
VALUE IN HEALTH | 2024年 / 27卷 / 06期
关键词：
D O I：
暂无
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
P14
引用
收藏
页码：S4 / S4
页数：1
相关论文
共 50 条
  • [21] Cost-effectiveness analysis of contraceptives available in United States
    Trussell, J.
    Lalla, A. M.
    Doan, Q., V
    Reyes, E.
    Pinto, L.
    Gricar, J. A.
    VALUE IN HEALTH, 2008, 11 (03) : A248 - A248
  • [22] Cost-effectiveness analysis of contraceptives available in the United States
    Trussell, J.
    Lalla, A.
    Pinto, L.
    Gricar, J.
    CONTRACEPTION, 2008, 78 (02) : 177 - 178
  • [23] Distributional Cost-Effectiveness Analysis of Health Technologies: Data Requirements and Challenges
    Meunier, Aurelie
    Longworth, Louise
    Kowal, Stacey
    Ramagopalan, Sreeram
    Love-Koh, James
    Fin, Susan Grif
    VALUE IN HEALTH, 2023, 26 (01) : 60 - 63
  • [24] Using Cost-Effectiveness Analysis to Address Health Equity Concerns
    Cookson, Richard
    Mirelman, Andrew J.
    Griffin, Susan
    Asaria, Miqdad
    Dawkins, Bryony
    Norheim, Ole Frithjof
    Verguet, Stephane
    Culyer, Anthony J.
    VALUE IN HEALTH, 2017, 20 (02) : 206 - 212
  • [25] COST-EFFECTIVENESS ANALYSIS OF THROMBOLYSIS WITH RECOMBINANT TISSUE PLASMINOGEN ACTIVATOR (ALTEPLASE) FOR ACUTE ISCHEMIC STROKE UNDER THE BRAZILIAN PUBLIC HEALTH CARE SYSTEM PERSPECTIVE
    Teich, V
    Passos, R. B. F.
    Vianna, D.
    VALUE IN HEALTH, 2009, 12 (07) : A503 - A503
  • [26] Distributional Cost-Effectiveness Analysis Comes of Age
    Cookson, Richard
    Griffin, Susan
    Norheim, Ole F.
    Culyer, Anthony J.
    Chalkidou, Kalipso
    VALUE IN HEALTH, 2021, 24 (01) : 118 - 120
  • [27] Cost-Effectiveness of Mechanical Thrombectomy of Ischemic Stroke
    Pan, Yuesong
    Cai, Xueli
    Wang, Yongjun
    Miao, Zhongrong
    Wang, Yilong
    STROKE, 2018, 49
  • [28] THE IMPACT OF FUNDING TOCILIZUMAB FOR THE INPATIENT TREATMENT OF COVID-19 IN THE UNITED STATES: A DISTRIBUTIONAL COST-EFFECTIVENESS ANALYSIS
    Rosettie, K. L.
    Best, J.
    Kowal, S.
    VALUE IN HEALTH, 2024, 27 (06) : S93 - S93
  • [29] Health-related quality of life measures for a cost-effectiveness analysis of ischemic stroke therapies
    Drugdova, Irena
    Rogalewicz, Vladimir
    Sramek, Martin
    Kopalova, Veronika
    Krahula, Ondrej
    Gavurova, Beata
    Bartak, Miroslav
    KONTAKT-JOURNAL OF NURSING AND SOCIAL SCIENCES RELATED TO HEALTH AND ILLNESS, 2020, 22 (02): : 128 - 136
  • [30] COST-EFFECTIVENESS OF ALTEPLASE TO TREAT ACUTE ISCHEMIC STROKE WITHIN 4.5 HOURS AFTER ONSET IN THE BRAZILIAN UNIFIED HEALTH SYSTEM PERSPECTIVE
    Campos, D. B.
    Martins, S. O.
    Safanelli, J.
    Santoni, N. B.
    Marcolino, M.
    Antonini Ribeiro, R.
    VALUE IN HEALTH, 2020, 23 : S626 - S627
12345